Clinical Trial Update: A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of tazemetostat in relapsed or refractory B-cell non-Hodgkin's lymphoma completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Tazemetostat (tazemetostat)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2022-11-10